Product Name: Met (1353-1359) pT1355+pY1356
Product Number: PE-04AEB99
| Size: | 200 µg | Price: | 66.00 | |
| 1 mg | $US | 132.00 | ||
| 5 mg | 290.00 |
Peptide Name: Met (1353-1359) pT1355+pY1356
Product Use: Services as a blocking peptide for use with the Met-pT1355+pY1356 rabbit polyclonal antibody (Cat. No.: AB-PK707) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the C-terminus of the kinase. This is the major in vivo phosphorylation sites in Met. Phosphorylation of Y1356 inhibits phosphotransferase activity. Phosphorylation also induces molecular association with FAK, GAB1, GRB2, Met, PIK3C2A, PIK3R1, PLCG1, Ron, Shc1, SHIP2, SOS1 and Src.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: NA-pT-pY-VNV
Product Use: Services as a blocking peptide for use with the Met-pT1355+pY1356 rabbit polyclonal antibody (Cat. No.: AB-PK707) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the C-terminus of the kinase. This is the major in vivo phosphorylation sites in Met. Phosphorylation of Y1356 inhibits phosphotransferase activity. Phosphorylation also induces molecular association with FAK, GAB1, GRB2, Met, PIK3C2A, PIK3R1, PLCG1, Ron, Shc1, SHIP2, SOS1 and Src.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: NA-pT-pY-VNV
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: βAla-Cys
Peptide Modifications Other: Phosphorylated
Peptide Molecular Mass Calculated: 1113.01 Da
Peptide Purity Percent after Synthesis and Purification: >95
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: Met - pT1355+pY1356 phosphosite-specific antibody (Cat. No.: AB-PK707)
Peptide Modifications C Terminus: βAla-Cys
Peptide Modifications Other: Phosphorylated
Peptide Molecular Mass Calculated: 1113.01 Da
Peptide Purity Percent after Synthesis and Purification: >95
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: Met - pT1355+pY1356 phosphosite-specific antibody (Cat. No.: AB-PK707)
Scientific Background: Met (HGFR) is a protein-tyrosine kinase of the TK group and Met family. It is activated by binding hepatocyte growth factor (HGF), which induces dimerization and autophosphorylation. Phosphorylation of Y1003 increases phosphotransferase activity and induces interaction with Cbl. Phosphorylation of Y1230 and Y1235 increases phosphotransferase activity. Phosphorylation of Y1234 increases phosphotransferase activity and induces interaction with Grb2. Phosphorylation of S985 inhibits phosphotransferase activity. Phosphorylation of Y1349 inhibits phosphotransferase activity, but induces interaction with FAK, Gab1, Grb2, Met, PIK3R1, PLCG1 and Src. Met mediates scattering, proliferation, survival, and morphogenesis of cells. Some immediate regulators that bind to Met after activation with HGF include PLCG1, PIK3R1, GRB2, SRC, STAT3 or the adapter GAB1. Met is a known oncoprotein (OP). Cancer-related mutations in human tumours point to a gain of function of the protein kinase. The active form of the protein kinase normally acts to promote tumour cell proliferation. Hepatocellular carcinoma (HCC) occurs with higher risk in those that have chronic HCV (hepatitis C virus) or HBV (hepatitis B virus) infection, or aflatoxin exposure in diet, or alcohol-induced cirrhosis, or another form of cirrhosis.
© Kinexus Bioinformatics Corporation 2017